Get the Stockscreener App
2.70
11.57%
0.28
After Hours:
2.64
-0.06
-2.22%
Mural Oncology Plc stock is traded at $2.70, with a volume of 5.72M.
It is up +11.57% in the last 24 hours and down -33.66% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.42
Open:
$2.5
24h Volume:
5.72M
Relative Volume:
1.31
Market Cap:
$17.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+171.30%
1M Performance:
-33.66%
6M Performance:
-26.83%
1Y Performance:
-28.19%
1-Day Range:
$2.43
$2.78
1-Week Range:
$0.98
$3.2099
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.70 | 17.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Mural Oncology (MURA) Shares Skyrocket Amid Major Corporate Shift - Stocks Telegraph
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com Canada
Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives - MSN
Mass. biotech company cuts 90% of workforce - Boston.com
Form 8.3Mural Oncology plc - Business Wire
BlackRock discloses stake in Mural Oncology - Investing.com
Promising Pharmaceutical Stocks To Consider – April 15th - Defense World
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
BlackRock discloses 1.76% stake in Mural Oncology By Investing.com - Investing.com South Africa
MURA Soars as it Explores Strategic Options Post Cancer Study Failures - TradingView
LMR Partners LLP discloses 2.89% stake in Mural Oncology - Investing.com
Mural shuts down lead programme and slashes 90% of staff - Yahoo Finance
Mural Oncology Sees Unusually High Options Volume (NASDAQ:MURA) - Defense World
Mural Oncology halts nemvaleukin trials, seeks strategic options By Investing.com - Investing.com South Africa
Biotech Company Sees Stock Boost Following Major Strategy Shift - The Globe and Mail
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On? - Benzinga
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Raymond James cuts Mural Oncology target to $4, retains outlook By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Massachusetts biotech company cuts 90% of its workforce - NBC Boston
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Mural Oncology Shares Jump as it Seeks Strategic Alternatives; Co. Discontinues Nemvaleukin Alfa Development - marketscreener.com
Mural Oncology halts nemvaleukin trials, seeks strategic options - Investing.com
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Mural Oncology Ends Nemvaleukin Program, Begins Strategic Review - Nasdaq
Mural Oncology Announces Plans To Explore Strategic Alternatives - MarketScreener
Mural Oncology Skyrockets on News of Strategic Shake-Up - Wall Street Pit
Mural Oncology to Explore Strategic Alternatives, Cut Workforce by 90%; Shares Jump Pre-Bell - MarketScreener
Why MURA Stock Goes Parabolic Today - Own Snap
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Failed Cancer Trial Forces Mural Oncology to Halt Development and Cut 90% of Workforce - Stock Titan
Research Analysts’ Recent Ratings Updates for Mural Oncology (MURA) - Defense World
Raymond James Financial Inc. Makes New Investment in Mural Oncology plc (NASDAQ:MURA) - Defense World
IL-2 ADding contenders in eczema strategy - BioWorld MedTech
Spin-Off Research Slashes Mural Oncology Valuation - Forbes
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer - Curetoday
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World
HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha
HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK
Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks
Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks
Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World
Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World
Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley - Defense World
Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):